My Web Dashboard





SEO News: Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of (FinanzNachrichten)

GENEVA, Switzerland, December 12 /PRNewswire-FirstCall/ -- Serono ( Nachrichten / Aktienkurs ) (virt-x: SEO and NYSE: SRA) announced today the initiation of a Phase III clinical trial to evaluate the effect of two dosage regimens of the new formulation of Rebif(R) (interferon beta-1a 44 mcg, three times a week or once a week) on the time to conversion to multiple sclerosis (MS) in people with

read more...

Related News